A bold insight emerges: tailoring delivery timing at term, guided by a 36-week risk screen, can safely lower the incidence of pre-eclampsia without adding new risks. But here’s where it gets controversial: does scheduling births at term truly improve outcomes across diverse populations, or are we trading flexibility for a controlled protocol? This rewrites the core findings and reasoning of the PREVENT-PE study in clearer terms for beginners, while preserving the essential information and implications.
Understanding the problem and the proposed solution
Pre-eclampsia is a leading cause of serious illness and death during pregnancy, affecting about 3% of pregnancies. Most term cases (around 75%) occur at or after 37 weeks. At term, pre-eclampsia accounts for a sizable share of maternal and perinatal complications, making effective prevention a high priority.
The study explored whether identifying women at risk at 36 weeks and then planning birth within a 37–40 week window could reduce term pre-eclampsia. This approach builds on previous work showing some benefits from inducing delivery earlier in high-risk pregnancies, but with a crucial twist: using personalized risk assessment to guide the timing.
What was done in the PREVENT-PE trial
- Design and setting: An open-label randomized controlled trial conducted at two UK maternity hospitals. Eligible participants were pregnant people aged 16 or older with a single baby and no major fetal anomalies, and none had pre-eclampsia at the start.
- Risk assessment: At 36 weeks, the FMF competing-risks model evaluated each participant’s risk of developing term pre-eclampsia. The model considers a blend of factors: maternal characteristics (age, weight, ethnicity, conception method), medical history (previous hypertensive disorders, chronic hypertension, diabetes, prior pre-eclampsia, family history, autoimmune disease), serum biomarkers (placental growth factor and soluble fms-like tyrosine kinase-1), and mean arterial pressure.
- Group assignment: Participants were randomized to either the intervention (risk-stratified planned birth) or standard care (usual care regardless of risk).
- Intervention logic: If a person’s 36-week risk of pre-eclampsia was 1 in 50 or higher, they were offered a plan for delivery between 37 and 40 weeks, with earlier timing for those at higher risk. About 78% of those in the intervention group were categorized as low risk and continued with standard care.
- Control group: Received usual pregnancy care, independent of risk status.
Who was studied and what were the baseline characteristics?
The final analysis included 8,094 women. The average participant was in their early thirties, with many having a higher body mass index. Racial demographics skewed toward White (about 74%). About half were first-time pregnancies, a small fraction had prior pregnancies affected by pre-eclampsia, and roughly 4% had a family history of the condition. The 36-week risk assessment was chosen because its predictions for term pre-eclampsia are most accurate at that point.
What were the results?
- Term pre-eclampsia occurrences: 4% (158 of 4,037) in the intervention group vs 5.6% (226 of 4,057) in the control group. This equates to a 30% relative reduction in risk when analyzed by intention to treat, using current diagnostic criteria.
- Safety: No differences in serious adverse events between groups, each below 0.3%. Importantly, there was no rise in postpartum pre-eclampsia, no increase in emergency cesarean sections, and no higher rate of neonatal intensive care unit admissions in the intervention group.
- Participation and acceptability: About three-quarters of eligible women enrolled, with minimal loss to follow-up, suggesting good acceptability of risk-guided timed birth at term.
What does this mean for practice and policy?
- Practical takeaway: For women identified as higher risk at 36 weeks, planning birth earlier within 37–40 weeks can lower the chance of term pre-eclampsia without adding maternal or neonatal risks, provided care pathways support risk-based decisions and timely delivery.
- Next steps: The researchers plan to assess the cost-effectiveness and gather qualitative insights from participants and clinicians. If results hold across broader settings, guidelines could incorporate 36-week risk screening and a structured term-birth plan for those at elevated risk.
Controversies and considerations for the audience
- Scope and generalizability: The study was conducted within UK maternity care settings. How would findings translate to different health systems, with varying access to ultrasound, biomarkers, and induction resources?
- Risk thresholds: The 1 in 50 risk cutoff was used here. Would other thresholds optimize balance between benefits, resource use, and patient preference in varied populations?
- Personal choice and autonomy: While risk-based planning can improve outcomes, it also shifts delivery timing into a more medicalized decision framework. What values should guide whether a patient accepts a planned early-term birth?
If you’re navigating late-pregnancy care, does this approach resonate with your priorities—minimizing complications while preserving choice and safety? What doubts or support do you have about risk-based timing of birth, and how might this influence guidelines in your healthcare setting?
